How JenaValve’s Trilogy THV System FDA Approval Could Impact the Global Heart Valve Replacement Procedures Market

In March 2026, JenaValve Technology received FDA premarket approval for its Trilogy Transcatheter Heart Valve (THV) System to treat symptomatic, severe native aortic regurgitation in patients at high or greater risk for surgical aortic valve replacement. The FDA approval establishes Trilogy as a dedicated transcatheter treatment option for this patient population in the United States.

The Trilogy THV System uses locator technology designed to attach to the native aortic valve leaflets rather than relying on annular calcification for anchoring. This design addresses a technical challenge of aortic regurgitation, where anatomy may not provide the same calcification-based anchoring conditions commonly present in aortic stenosis.

The approval adds a dedicated transcatheter option to the heart valve replacement procedures market and expands the role of transcatheter aortic valve replacement beyond traditional aortic stenosis applications. According to Knowledge Sourcing Intelligence (KSI), the global heart valve replacement procedures market is projected to grow at a CAGR of 7.2%, reaching USD 26.7 billion in 2031 from USD 18.9 billion in 2026.

Recent Developments in the Heart Valve Replacement Procedures Market

• May 2026: Abbott launched the TriClip transcatheter edge-to-edge repair system in India for patients with tricuspid regurgitation, extending minimally invasive structural heart treatment in the market.

• April 2026: Medtronic announced the U.S. launch of its Mosaic Neo mitral bioprosthesis following FDA approval, expanding surgical valve replacement options across sternotomy, minimally invasive, and robotic procedures.

• April 2026: JenaValve announced the U.S. commercial launch of the Trilogy THV System following FDA approval, with initial commercial procedures performed at NewYork-Presbyterian/Columbia University Irving Medical Center, Cedars-Sinai Medical Center, and Piedmont Heart Institute.

How This Reshapes Heart Valve Replacement Competition

The Trilogy THV System could intensify competition in transcatheter heart valve replacement by addressing severe aortic regurgitation, a condition with different anchoring requirements from calcific aortic stenosis. Its leaflet-based locator technology provides an alternative approach to valve positioning and fixation. The FDA approval also expands the addressable patient population for transcatheter interventions among patients at high or greater surgical risk. Competitors may respond by developing procedure-specific valves, delivery systems, and anatomical solutions for aortic regurgitation and other similar structural heart conditions. Hospitals can assess these technologies based on approved indications, clinical evidence, procedural workflow, physician expertise, device availability, and overall treatment economics.

How Knowledge Sourcing Intelligence’s (KSI) Heart Valve Replacement Procedures Market Report Can Help

Knowledge Sourcing Intelligence’s Global Heart Valve Replacement Procedures Market report provides market analysis across valve replacement procedures, technologies, applications, end users, and geographic markets. The report enables stakeholders to examine the development of transcatheter and surgical approaches and assess how regulatory approvals such as the Trilogy THV System can affect competitive and procedural dynamics.

The market analysis covers regional opportunities across North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The report also assesses factors influencing demand for heart valve replacement procedures, including demographic trends, technological development, healthcare infrastructure, and adoption of minimally invasive interventions.

Request a free sample copy or view the report summary: Heart Valve Replacement Procedures Market Report

Heart Valve Replacement Procedures Market Highlights

• Transcatheter procedures are expanding treatment options, particularly for patients requiring less invasive approaches to valve replacement.

• Aortic regurgitation represents an important treatment area, with dedicated technologies addressing anatomical challenges associated with valve anchoring.

• Disease-specific valve technologies are increasing, as manufacturers develop systems for different valve positions and patient anatomies.

• Regulatory approvals remain important, influencing the availability, indications, and commercialization of new heart valve replacement technologies.

Heart Valve Replacement Procedures Market Growth Drivers and Restraints

Growth Drivers:

• Aging Population and Valvular Disease: Population aging is increasing the number of patients affected by degenerative heart valve disorders, supporting demand for valve replacement procedures across healthcare systems.

• Expansion of Transcatheter Interventions: Continued development of TAVR and other transcatheter technologies is expanding minimally invasive treatment options and allowing manufacturers to address patient groups with different anatomical and surgical-risk profiles.

• Technology Development: Advances in valve design, delivery systems, tissue technologies, and anatomical positioning are supporting the development of procedure-specific heart valve replacement solutions.

Restraints:

• High Procedure and Device Costs: Transcatheter valve procedures require specialized devices, imaging, hospital infrastructure, and trained clinical teams, which can increase treatment costs and restrict adoption in resource-constrained healthcare systems.

• Regulatory and Clinical Evidence Requirements: New valve technologies require extensive regulatory review and clinical evidence before commercialization, increasing development timelines and investment requirements for manufacturers.

• Specialized Clinical Expertise: Heart valve replacement procedures require multidisciplinary teams and specialized procedural capabilities, which can limit access in healthcare systems with shortages of trained cardiovascular specialists or structural-heart infrastructure.

Heart Valve Replacement Procedures Market Segmentation

Heart Valve Replacement Procedures Market Key Players

• Edwards Lifesciences

• Medtronic

• Abbott Laboratories

• Boston Scientific

• Artivion

• LivaNova

• JenaValve Technology

• Meril Life Sciences

• Corcym

• Braile Biomedica